Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood (2023) 142 (16): 1359–1370.

https://doi.org/10.1182/blood.2023020485

Published: 2023

Includes: Supplemental data

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-136384

Published: 2020

Journal Articles

Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma

Atish Mohanty, Natalie Sandoval, An Phan, Thang V. Nguyen, Robert W. Chen, Elizabeth Budde, Matthew Mei, Leslie Popplewell, Lan V. Pham, Larry W. Kwak, Dennis D. Weisenburger, Steven T. Rosen, Wing C. Chan, Markus Müschen, Vu N. Ngo

Blood (2019) 133 (4): 306–318.

https://doi.org/10.1182/blood-2018-05-851667

Published: 2019

Includes: Supplemental data

Journal Articles

Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Lu Chen, PhD, Alex F. Herrera, MD, Matthew Mei, MD, Katrina McBride, Rosie Abary, Tanya Siddiqi, MD, Leslie Popplewell, MD, Stephen J Forman, Steven T Rosen, Larry W Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2018-99-110403

Published: 2018

Journal Articles

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Blood (2018) 132 (Supplement 1): 1596.

https://doi.org/10.1182/blood-2018-99-110334

Published: 2018

Journal Articles

CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL

Leslie Popplewell, MD, Xiuli Wang, PhD, Suzette Blanchard, PhD, Jamie Wagner, BS, Araceli Naranjo, BS, Arencibia Adria, BS, Jinny Paul, PhD, Laura Lim, Wen-Chung Chang, PhD, Elizabeth E Budde, MD PhD, Sandra Thomas, PhD, Christine Brown, PhD, Stephen J Forman

Blood (2018) 132 (Supplement 1): 610.

https://doi.org/10.1182/blood-2018-99-119650

Published: 2018

Journal Articles

The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma

Xiuli Wang, PhD, Christian Huynh, Ryan Urak, Miriam Walter, Lihong Weng, MD, Laura Lim, Vibhuti Vyas, Brenda Aguilar, Alfonso Brito, Aniee Sarkissian, Achini Bandara, PhD, Elizabeth E Budde, MD PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Christine Brown, PhD, Stephen J Forman

Blood (2018) 132 (Supplement 1): 965.

https://doi.org/10.1182/blood-2018-99-119335

Published: 2018

Journal Articles

Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation

Alex Iukuridze, Meisi Xiao, MPH, Lee Brandyn, Jennifer Berano Teh, Kristen Mascarenhas, Sandra Xu, Nicholas Rosen, Jeannine S McCune, PharmD, Jasmine M. Zain, MD, Robert W. Chen, MD, Leslie Popplewell, MD, Jessica Scott, PhD, Thomas Slavin, MD, Lee Jones, PhD, Stephen J Forman, Ryotaro Nakamura, MD, F. Lennie Wong, PhD, Saro H. Armenian, DO,MPH

Blood (2018) 132 (Supplement 1): 620.

https://doi.org/10.1182/blood-2018-99-113689

Published: 2018

Journal Articles

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

Robert W. Chen, MD, Joycelynne M. Palmer, PhD, Leslie Popplewell**, MD, Jessica Alluin, Pritsana Chomchan, Auayporn P. Nademanee, MDBS, Tanya Siddiqi, MD, Nicole Tsai, Fay Zuo, Rosie Abary, Ji-lian Cai, Steven T. Rosen, MD, Stephen J. Forman, MD FACP, Larry W Kwak, MDPhD, Leona Holmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4515.

https://doi.org/10.1182/blood.V130.Suppl_1.4515.4515

Published: 2017

Journal Articles

Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Joycelynne M. Palmer, PhD, Alex Francisco Herrera, MD, Saro H. Armenian, DO,MPH, Matthew Mei, MD, Leslie Popplewell**, MD, Abbey Fueger, Imran Qasim, Tracy Stiller, Steven T. Rosen, MD, Stephen J. Forman, MD FACP, Larry W Kwak, MDPhD

Blood (2017) 130 (Supplement 1): 738.

https://doi.org/10.1182/blood.V130.Suppl_1.738.738

Published: 2017

Journal Articles

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Joseph Tuscano, MD, Susan Groshen, PhD, Denice Tsao-Wei, Emanual Maverakis, MD, Paul R. Kaesberg, MD, Tanya Siddiqi, MD, Leslie Popplewell**, MD, Sikander Ailawadhi, Myo Htut, Robert W. Chen, MD, Mark Kirschbaum, MD, Mark T. Schroeder, MD, Brian A Jonas, MD PhD, Ted Wun, MD FACP, FRCPA, Neil Palmisiano, MD, David F. Claxton, Edward Newman, PhD

Blood (2017) 130 (Supplement 1): 4086.

https://doi.org/10.1182/blood.V130.Suppl_1.4086.4086

Published: 2017

Journal Articles

New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells

Xiuli Wang, MD PhD, Ryan Urak, MS, Walter Miriam, MS, Laura Lim, BS, Brenda Aguilar, BS, Alfonso Brito, BS, Aniee Sarkissian, BS, Christine Brown, PhD, Sandra H. Thomas, PhD, Leslie Popplewell, MD, Lihua E. Budde, MD PhD, Stephen J. Forman, MD

Blood (2016) 128 (22): 2161.

https://doi.org/10.1182/blood.V128.22.2161.2161

Published: 2016

Journal Articles

Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation

Blood (2016) 128 (22): 830.

https://doi.org/10.1182/blood.V128.22.830.830

Published: 2016

Journal Articles

Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

Barbara Marie Galligan, MD, Denice Tsao-Wei, Susan Groshen, Mark Kirschabum, Robert O'Donnell, Paul R. Kaesberg, MD, Tanya Siddiqui, Leslie Popplewell, Ailawadhi Sikander, Htut Myo, Robert Chen, John F. DiPersio, MD PhD, Neil D. Palmisiano, MD, David F. Claxton, MD, Edward M. Newman, PhD, Joseph Tuscano, MD

Blood (2015) 126 (23): 3977.

https://doi.org/10.1182/blood.V126.23.3977.3977

Published: 2015

Journal Articles

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Leslie Popplewell, MD, Xiuli Wang, PhD, Araceli Naranjo, BS, Suzette Blanchard, PhD, Jamie Wagner, BS, ChingLam Wong, BS, Ryan Urak, MS, Wen-Chung Chang, MS, Samer K Khaled, MD, Tanya Siddiqi, MD, Elizabeth E. Budde, MD PhD, Jingying Xu, PhD, Brenda Chang, BS, Sandra H. Thomas, PhD, Stanley R. Riddell, MD, Christine Brown, PhD, Michael C Jensen, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 930.

https://doi.org/10.1182/blood.V126.23.930.930

Published: 2015

Journal Articles

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Tanya Siddiqi, MD, Anna Scuto, PhD, Jan H. Beumer, PharmD, PhD, Joo Y. Song, MD, Paul Frankel, PhD, Chris Ruel, MS, Jacob Cobb, BS, Brian F. Kiesel, BS, Dennis D. Weisenburger, MD, Kevin R. Kelly, MD PhD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, PhD MD, Edward M. Newman, PhD

Blood (2015) 126 (23): 2731.

https://doi.org/10.1182/blood.V126.23.2731.2731

Published: 2015

Journal Articles

Circulating reactive plasma cells in the setting of peripheral T-cell lymphoma mimicking plasma cell leukemia

Joo Y. Song, Leslie Popplewell

Blood (2015) 126 (9): 1150.

https://doi.org/10.1182/blood-2015-05-648311

Published: 2015

Journal Articles

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

Tanya Siddiqi, MD, Paul Frankel, PhD, Chris Ruel, MS, Robert W Chen, MD, Kevin R. Kelly, MD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, MD PhD, Edward Newman, PhD

Blood (2014) 124 (21): 4483.

https://doi.org/10.1182/blood.V124.21.4483.4483

Published: 2014

NARROW

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma

Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL

The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma

Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells

Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation

Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Circulating reactive plasma cells in the setting of peripheral T-cell lymphoma mimicking plasma cell leukemia

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only